Patent ID: 8697071
Filing Date: 2014-04-15
Classification: A61K,A61P,C07K,G01N

Abstract:
1. A method of increasing antibody-dependent cell mediated cytotoxicity (ADCC) activity by administering to a subject a therapeutically effective amount of an antibody, or an antigen-binding fragment thereof, wherein said antibody or said antigen-binding fragment thereof comprises a variant Fc region including amino acid modifications relative to a wild-type Fc region such that said variant Fc region binds FcγRIIIA with a greater affinity relative to an antibody comprising the wild-type Fc region, and wherein said included amino acid modifications comprise: (A) a substitution at position 243 with leucine, a substitution at position 292 with proline, a substitution at position 300 with leucine, a substitution at position 305 with isoleucine, and a substitution at position 396 with leucine; (B) a substitution at position 243 with leucine, a substitution at position 292 with proline, a substitution at position 300 with leucine, and a substitution at position 396 with leucine; or (C) a substitution at position 243 with leucine, a substitution at position 292 with proline, and a substitution at position 300 with leucine; wherein the positions are numbered according to the EU index as in Kabat.